Clinical Trial: Intestinal Levodopa + Entacapone Therapy (Lecigon(R)) to Counteract Dopaminergic Desensitization and Neuropsychiatric Complications in Parkinson's Disease

U.S., Sept. 4 -- ClinicalTrials.gov registry received information related to the study (NCT07151378) titled 'Intestinal Levodopa + Entacapone Therapy (Lecigon(R)) to Counteract Dopaminergic Desensitization and Neuropsychiatric Complications in Parkinson's Disease' on June 27.

Brief Summary: This study is a Phase III multicentric randomized controlled trial with parallel group design and waiting list in patients that have an indication to undergo intestinal L-Dopa + entacapone (Lecigon(R)) under the existing indication criteria (according to SmPC (Fachinformation) Lecigon(R)). As primary endpoint, we will analyze the difference of the pre-interventional baseline and 6-month follow-up on the "hyperdopaminergic symptoms" corresponding to sect...